Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer-Reference-Cited by-同舟云学术

Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer

Published:2014-10 Issue:4 Volume:66 Page:655-663
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Boccon-Gibod Laurent,Albers Peter,Morote Juan,van Poppel Hendrik,de la Rosette Jean,Villers Arnauld,Malmberg Anders,Neijber Anders,Montorsi Francesco

Publisher

Elsevier BV

Subject

Urology

Reference31 articles.

1. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists;Van Poppel;Int J Urol,2012

2. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/Prostate%20Cancer%202010%20June%2017th.pdf. Updated 2010.

3. The development of androgen-independent prostate cancer;Feldman;Nat Rev Cancer,2001

4. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer;Spry;Eur J Cancer,2006

5. Intermittent androgen suppression for rising PSA level after radiotherapy;Crook;N Engl J Med,2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19);Journal of Clinical Oncology;2024-04-01

2. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials;Signal Transduction and Targeted Therapy;2022-06-24

3. Effectiveness of GnRH Antagonists and Agonists in Patients with Hormone-Sensitive Prostate Cancer: A Retrospective Study;Applied Bionics and Biomechanics;2022-06-09

4. Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network;European Journal of Cancer;2021-09

5. Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [18F]DCFPyL PET Imaging;Molecular Imaging and Biology;2021-04-23